Multiple Myeloma Excellence Forum

Multiple Myeloma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Brea Lipe, University of Rochester Medical Center

Conference Coverage

Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?

04/16/2024

Featuring Brea Lipe, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.

During the 2024 Great Debates &...

04/16/2024

Oncology

Conference Coverage

Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting

04/10/2024

Featuring Ashley Rosko, MD

Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...

Ashley Rosko, MD, discusses...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?

04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...

At the 2024 Great Debates &...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment

04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.

During the 2024 Great Debates &...

04/09/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Analyzing Comprehensive Health of Patients With Multiple Myeloma for Transplant Decision-Making

04/08/2024

Featuring Ashley Rosko, MD

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...

At the 2024 Great Debates &...

04/08/2024

Oncology

Conference Coverage

Should Additional BCMA Therapy be Utilized After Previous BCMA Therapy?

04/08/2024

Featuring Andrew Yee, MD

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.

At the 2024 Great Debates &...

04/08/2024

Oncology

Conference Coverage

Exploring Promising Novel Advances in the Multiple Myeloma Treatment Landscape

04/05/2024

Featuring Joshua Richter, MD

Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.

Joshua Richter, MD, discusses...

04/05/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Should MRD-Based Decision-Making be Utilized in Multiple Myeloma Treatment Strategies?

04/05/2024

Featuring Joshua Richter, MD

At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...

At the 2024 Great Debates &...

04/05/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Section Editor

Shaji Kumar, MD

Mayo Clinic, Rochester, Minnesota

Multiple Myeloma Excellence Forum

Section Editor

Specialties

Events

Year Round Education

HMP Global Products